Intech Investment Management LLC Raises Stake in Dynavax Technologies Co. (NASDAQ:DVAX)

Intech Investment Management LLC lifted its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 43.3% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 53,566 shares of the biopharmaceutical company’s stock after acquiring an additional 16,186 shares during the period. Intech Investment Management LLC’s holdings in Dynavax Technologies were worth $684,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Smartleaf Asset Management LLC raised its stake in Dynavax Technologies by 463.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 2,034 shares during the period. GAMMA Investing LLC raised its position in shares of Dynavax Technologies by 55.1% during the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock valued at $52,000 after buying an additional 1,457 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new position in Dynavax Technologies in the fourth quarter valued at approximately $71,000. Nisa Investment Advisors LLC grew its position in Dynavax Technologies by 19.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company’s stock worth $83,000 after acquiring an additional 1,076 shares during the period. Finally, Wilmington Savings Fund Society FSB acquired a new stake in Dynavax Technologies during the third quarter worth $89,000. Institutional investors and hedge funds own 96.96% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on DVAX shares. The Goldman Sachs Group lowered Dynavax Technologies from a “neutral” rating to a “sell” rating and decreased their price target for the company from $15.00 to $12.00 in a research note on Tuesday, February 11th. HC Wainwright reaffirmed a “buy” rating and issued a $31.00 target price on shares of Dynavax Technologies in a research report on Friday, February 21st. StockNews.com upgraded shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Monday, February 24th. Finally, William Blair restated an “outperform” rating on shares of Dynavax Technologies in a report on Friday, February 21st.

Dynavax Technologies Price Performance

DVAX stock opened at $13.82 on Monday. The business’s fifty day moving average price is $13.22 and its 200 day moving average price is $12.41. Dynavax Technologies Co. has a 12-month low of $9.74 and a 12-month high of $14.63. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $1.71 billion, a PE ratio of 76.78 and a beta of 1.23.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.05. The company had revenue of $72.03 million for the quarter, compared to analyst estimates of $72.70 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. On average, sell-side analysts anticipate that Dynavax Technologies Co. will post 0.32 EPS for the current year.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.